Philadelphia, August 27, 2025
News Summary
Kite, a biopharmaceutical company under Gilead Sciences, has agreed to acquire Interius BioTherapeutics for $350 million. This acquisition will enhance Kite’s capabilities in developing in vivo CAR therapeutics, potentially improving patient outcomes and treatment timelines. The transaction is set to establish a new center of excellence in Philadelphia, integrating Interius’s innovative platforms into Kite’s research team, marking a significant advancement in therapy delivery methods.
Kite Acquires Interius BioTherapeutics for $350 Million
California – Kite, a globally recognized biopharmaceutical company owned by Gilead Sciences Inc., has announced a definitive agreement to acquire Philadelphia-based Interius BioTherapeutics for $350 million. This strategic move aims to enhance Kite’s capabilities in the development of in vivo chimeric antigen receptor (CAR) therapeutics.
This acquisition involves Kite purchasing all outstanding share capital of Interius, with payment due upon closing. Post-acquisition, Interius employees and operations will be integrated into Kite’s existing research team, establishing a new center of excellence in Philadelphia focused on the development of next-generation in vivo therapies.
According to Kite’s executive team, the acquisition signifies a major advancement in in vivo therapy, which has the potential to shorten treatment timelines and improve patient outcomes. Interius’s innovative platform is designed to generate ex vivo CAR T-cells directly within the patient’s body by integrating DNA into their genome.
Innovative Treatment Approach
The in vivo technique employed by Interius BioTherapeutics offers a significant departure from traditional CAR T therapies, which require a multi-step process of cell harvesting, engineering, and reinfusion. Instead, Interius’s methodology allows for potential delivery through a single intravenous infusion without the necessity for preconditioning chemotherapy, thereby simplifying the treatment process.
This modular architecture makes the Interius platform adaptable across a variety of disease states, particularly enhancing access to cell therapies for patients who are suffering from rapidly progressing diseases. This capability is expected to significantly broaden the scope of available therapies and improve treatment outcomes for a wider range of patients.
Operational Integration and Financial Considerations
Cindy Perettie, Executive Vice President of Kite, has indicated that merging Interius’s innovative platform with Kite’s existing expertise promises to advance the development of in vivo therapies more efficiently. The acquisition agreement stipulates a cash payment of $350 million, subject to customary adjustments. However, it is projected that this deal will reduce Gilead’s GAAP and non-GAAP earnings per share by approximately $0.23-$0.25 in 2025.
The effective closing of the transaction is contingent upon the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and fulfillment of other customary regulatory conditions. Financial advisory services for the transaction are being provided by TD Cowen for Kite and Evercore for Interius.
Company Background
Kite has established itself as a leader in cell therapy, treating more patients with CAR T-cell therapy than any other company globally. Meanwhile, Gilead Sciences has over three decades of experience in achieving medical breakthroughs and operates in more than 35 countries, ensuring a strong foundation for their continued success in the biopharmaceutical industry.
Interius BioTherapeutics is known for engineering targeted, programmable vectors that facilitate the precision delivery of genetic medicines aimed at treating a range of complex diseases. By merging with Kite, Interius is poised to expand its reach and effectiveness in the ever-evolving landscape of therapeutic solutions.
FAQ
- What is the purpose of Kite acquiring Interius BioTherapeutics?
The acquisition aims to enhance Kite’s development of in vivo CAR therapeutics, particularly to improve patient outcomes and reduce treatment timelines. - How much is Kite paying for Interius BioTherapeutics?
Kite has agreed to pay $350 million in cash for Interius’s outstanding share capital. - Where will the operations of Interius BioTherapeutics be integrated?
Interius’s operations and employees will be integrated into Kite’s research team, establishing a center of excellence in Philadelphia. - What distinguishes Interius’s therapy from traditional CAR T therapies?
Unlike traditional therapies that require cell harvesting and reinfusion, Interius’s approach can be delivered through a single intravenous infusion without preconditioning chemotherapy. - What impact will the acquisition have on Gilead’s earnings?
The deal is projected to reduce Gilead’s GAAP and non-GAAP EPS by approximately $0.23-$0.25 in 2025.
Key Features of the Acquisition
| Feature | Details |
|---|---|
| Acquisition Cost | $350 million in cash |
| Integration Location | Philadelphia – center of excellence |
| Treatment Method | In vivo CAR therapy delivered via single infusion |
| Impact on Gilead’s EPS | Reduction by approx. $0.23-$0.25 in 2025 |
| Advisors | TD Cowen (Kite), Evercore (Interius) |
Deeper Dive: News & Info About This Topic
- Business Wire
- Wikipedia: Chimeric Antigen Receptor
- Penn Biz Report
- Google Search: Kite Acquires Interius BioTherapeutics
- Reuters
- Google Scholar: In vivo CAR therapeutics
- Ainvest
- Encyclopedia Britannica: CAR therapy
- MSN
- Google News: Kite Interius acquisition
Author: STAFF HERE HOLLYWOOD
The Hollywood Staff Writer represents the experienced team at HEREHollywood.com, your go-to source for actionable local news and information in Hollywood, Los Angeles County, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as the Hollywood Bowl summer concerts, the Hollywood Christmas Parade, film premieres at TCL Chinese Theatre, and festivals at the Magic Castle. Our coverage extends to key organizations like the Hollywood Chamber of Commerce and Visit Hollywood, plus leading businesses in entertainment, dining, and tourism that define the local economy. As part of the broader HERE network, including HERELosAngeles.com, HEREBeverlyHills.com, HEREAnaheim.com, and HEREHuntingtonBeach.com, we provide comprehensive, credible insights into Southern California's dynamic landscape.
